Tom 9, Nr 4 (2017)
Artykuły
Opublikowany online: 2018-07-20
Wyświetlenia strony
931
Wyświetlenia/pobrania artykułu
120
Zastosowanie bizmutu w leczeniu zakażenie Helicobacter Pylori
Gastroenterologia Kliniczna 2017;9(4):95-97.
Streszczenie
Brak
Referencje
- Warren JR, Marshall BJ. Unidentified curved bacilii on gastric epithelium in active chronic gastritis. Lancet. 1983; 1(8336): 1273–1275.
- IARC monographs on the evaluation of carcinogenic risks to humans. Lyon: World Health Organisation. 1994: 177–240.
- Rugge M, Genta RM, Di Mario F, et al. Gastric Cancer as Preventable Disease. Clin Gastroenterol Hepatol. 2017; 15(12): 1833–1843.
- Hooi JKY, Lai WY, Ng WK, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology. 2017; 153(2): 420–429.
- Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut. 2004; 53(9): 1374–1384.
- Fallone CA, Chiba N, van Zanten SV, et al. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology. 2016; 151(1): 51–69.e14.
- Axon A. Helicobacter pylori in the Pathogenesis of Peptic Ulcer — Evidence in Favour. Helicobacter pylori, Gastritis and Peptic Ulcer. 1990: 345–349.
- Wilson P, Alp MH. Colloidal bismuth subcitrate tablets and placebo in chronic duodenal ulceration: a double-blind, randomised trial. Med J Aust. 1982; 1(5): 222–223.
- Sun Q, Liang X, Zheng Q, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010; 15(3): 233–238.
- Salazar CO, Cardenas VM, Reddy RK, et al. Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: a pilot study in US Hispanics. Helicobacter. 2012; 17(5): 382–390.
- Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. The Lancet. 2011; 377(9769): 905–913.
- Chey WD, Leontiadis GI, Howden CW, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017; 112(2): 212–239.
- Malfertheiner P, Megraud F, O'Morain CA, et al. European Helicobacter and Microbiota Study Group and Consensus panel. Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut. 2017; 66(1): 6–30.
- Yuan Y, Ford AC, Khan KJ, et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database Syst Rev. 2013(12): CD008337.
- McNicholl AG, Linares PM, Nyssen OP, et al. Meta-analysis: esomeprazole or rabeprazole vs. first-generation pump inhibitors in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther. 2012; 36(5): 414–425.
- Strzeszyński L. Postępowanie w przypadku zakażenia Helicobacter pylori. Podsumowanie raportu uzgodnieniowego Maastricht V/Florencja. Med Prakt. 2017; 4: 14–23.
